Journal article

A phase II trial using etanercept, a recombinant tumour necrosis factor antagonist, in metastatic breast cancer

Publication status:: Published

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Forster, M. D., Braybrooke, J., Madhusudan, S., Kaur, K., Hoare, S., Balkwill, F., Ganesan, T., Talbot, D., & Harris, A. (2002). A phase II trial using etanercept, a recombinant tumour necrosis factor antagonist, in metastatic breast cancer. BRITISH JOURNAL OF CANCER, 86, S38–S38.

MLA Style

Forster, M. D., et al. “A Phase II Trial Using Etanercept, a Recombinant Tumour Necrosis Factor Antagonist, in Metastatic Breast Cancer.” BRITISH JOURNAL OF CANCER, vol. 86, 2002, pp. S38–S38.

Chicago Style

Forster, MD, J Braybrooke, S Madhusudan, K Kaur, S Hoare, F Balkwill, T Ganesan, D Talbot, and A Harris. 2002. “A Phase II Trial Using Etanercept, a Recombinant Tumour Necrosis Factor Antagonist, in Metastatic Breast Cancer.” BRITISH JOURNAL OF CANCER 86: S38–S38.
Share
Print

Authors

+ Forster, MD More by this author

Role:: Author

+ Braybrooke, J More by this author

Role:: Author

+ Madhusudan, S More by this author

Role:: Author

+ Kaur, K More by this author

Role:: Author

+ Hoare, S More by this author

Role:: Author

More authors...

Journal:: BRITISH JOURNAL OF CANCER More from this journal
Volume:: 86
Pages:: S38-S38
Publication date:: 2002-06-01
ISSN:: 0007-0920

Pubs id:: pubs:175294
UUID:: uuid:8448da1c-ee99-4ba0-a915-a98199bd4908
Local pid:: pubs:175294
Source identifiers:: 175294
Deposit date:: 2012-12-19

Terms of use

Copyright date:: 2002

Licence:: Terms and Conditions of Use for Oxford University Research Archive

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP